Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 43% ± 14% | |
peripheral blood | 17 studies | 37% ± 10% | |
intestine | 12 studies | 40% ± 21% | |
kidney | 8 studies | 32% ± 11% | |
liver | 7 studies | 40% ± 17% | |
bone marrow | 6 studies | 34% ± 9% | |
brain | 6 studies | 29% ± 7% | |
pancreas | 5 studies | 63% ± 22% | |
eye | 5 studies | 27% ± 9% | |
lymph node | 5 studies | 35% ± 17% | |
placenta | 4 studies | 71% ± 29% | |
uterus | 4 studies | 45% ± 22% | |
prostate | 4 studies | 27% ± 5% | |
breast | 4 studies | 41% ± 7% | |
heart | 3 studies | 22% ± 9% | |
adrenal gland | 3 studies | 34% ± 9% | |
esophagus | 3 studies | 55% ± 29% | |
skin | 3 studies | 34% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 98341.86 | 328 / 328 | 100% | 405.60 | 178 / 178 |
esophagus | 100% | 23219.74 | 1444 / 1445 | 100% | 364.87 | 183 / 183 |
prostate | 100% | 21685.39 | 245 / 245 | 100% | 853.38 | 501 / 502 |
liver | 100% | 56600.91 | 226 / 226 | 100% | 710.76 | 404 / 406 |
lung | 100% | 24188.64 | 576 / 578 | 100% | 532.36 | 1153 / 1155 |
skin | 100% | 40625.00 | 1809 / 1809 | 99% | 497.29 | 469 / 472 |
stomach | 100% | 27816.61 | 359 / 359 | 99% | 414.76 | 284 / 286 |
breast | 100% | 18443.20 | 459 / 459 | 99% | 489.61 | 1108 / 1118 |
intestine | 100% | 17655.18 | 966 / 966 | 99% | 454.57 | 522 / 527 |
ovary | 100% | 14370.07 | 180 / 180 | 99% | 272.59 | 425 / 430 |
uterus | 100% | 14986.85 | 170 / 170 | 99% | 438.55 | 453 / 459 |
bladder | 100% | 17349.76 | 21 / 21 | 98% | 467.03 | 494 / 504 |
thymus | 100% | 19761.83 | 653 / 653 | 97% | 266.65 | 587 / 605 |
kidney | 100% | 16056.39 | 89 / 89 | 97% | 391.57 | 872 / 901 |
adrenal gland | 100% | 34855.95 | 258 / 258 | 87% | 227.91 | 201 / 230 |
brain | 64% | 4009.57 | 1693 / 2642 | 91% | 155.99 | 642 / 705 |
adipose | 100% | 19093.94 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 28696.81 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 377.58 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 174.55 | 1 / 1 |
muscle | 100% | 16596.43 | 801 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 22051.25 | 1330 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 277.55 | 79 / 80 |
peripheral blood | 97% | 17703.69 | 902 / 929 | 0% | 0 | 0 / 0 |
heart | 95% | 14851.70 | 822 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 195.32 | 27 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0018401 | Biological process | peptidyl-proline hydroxylation to 4-hydroxy-L-proline |
GO_0098761 | Biological process | cellular response to interleukin-7 |
GO_0034976 | Biological process | response to endoplasmic reticulum stress |
GO_0046598 | Biological process | positive regulation of viral entry into host cell |
GO_0045785 | Biological process | positive regulation of cell adhesion |
GO_0038155 | Biological process | interleukin-23-mediated signaling pathway |
GO_0006457 | Biological process | protein folding |
GO_0034975 | Biological process | protein folding in endoplasmic reticulum |
GO_1902175 | Biological process | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway |
GO_0035722 | Biological process | interleukin-12-mediated signaling pathway |
GO_1900026 | Biological process | positive regulation of substrate adhesion-dependent cell spreading |
GO_0006888 | Biological process | endoplasmic reticulum to Golgi vesicle-mediated transport |
GO_0030070 | Biological process | insulin processing |
GO_0071456 | Biological process | cellular response to hypoxia |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005576 | Cellular component | extracellular region |
GO_0070062 | Cellular component | extracellular exosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005925 | Cellular component | focal adhesion |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0016222 | Cellular component | procollagen-proline 4-dioxygenase complex |
GO_0005793 | Cellular component | endoplasmic reticulum-Golgi intermediate compartment |
GO_0034663 | Cellular component | endoplasmic reticulum chaperone complex |
GO_0042470 | Cellular component | melanosome |
GO_0030027 | Cellular component | lamellipodium |
GO_0016972 | Molecular function | thiol oxidase activity |
GO_0019899 | Molecular function | enzyme binding |
GO_0015035 | Molecular function | protein-disulfide reductase activity |
GO_0005178 | Molecular function | integrin binding |
GO_0003723 | Molecular function | RNA binding |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0003756 | Molecular function | protein disulfide isomerase activity |
GO_0005515 | Molecular function | protein binding |
GO_0003779 | Molecular function | actin binding |
GO_0004656 | Molecular function | procollagen-proline 4-dioxygenase activity |
Gene name | P4HB |
Protein name | Protein disulfide-isomerase (EC 5.3.4.1) Protein disulfide-isomerase (PDI) (EC 5.3.4.1) (Cellular thyroid hormone-binding protein) (Prolyl 4-hydroxylase subunit beta) (p55) protein disulfide-isomerase (EC 5.3.4.1) Alternative protein P4HB (OK/SW-CL.24) Prolyl 4-hydroxylase subunit beta |
Synonyms | ERBA2L PDIA1 PDI OK/SW-cl.24 PO4DB hCG_95895 |
Description | FUNCTION: This multifunctional protein catalyzes the formation, breakage and rearrangement of disulfide bonds. At the cell surface, seems to act as a reductase that cleaves disulfide bonds of proteins attached to the cell. May therefore cause structural modifications of exofacial proteins. Inside the cell, seems to form/rearrange disulfide bonds of nascent proteins. At high concentrations and following phosphorylation by FAM20C, functions as a chaperone that inhibits aggregation of misfolded proteins . At low concentrations, facilitates aggregation (anti-chaperone activity). May be involved with other chaperones in the structural modification of the TG precursor in hormone biogenesis. Also acts as a structural subunit of various enzymes such as prolyl 4-hydroxylase and microsomal triacylglycerol transfer protein MTTP. Receptor for LGALS9; the interaction retains P4HB at the cell surface of Th2 T helper cells, increasing disulfide reductase activity at the plasma membrane, altering the plasma membrane redox state and enhancing cell migration . . |
Accessions | ENST00000571617.2 ENST00000679366.1 I3L3U6 ENST00000680083.1 ENST00000680914.1 P07237 ENST00000680226.1 ENST00000680732.1 B3KTQ9 A0A7P0T9U6 A0A7P0TA35 Q96C96 A0A7P0TBA3 I3NI03 A0A7P0TB26 A0A7P0T9E3 ENST00000680259.1 A0A7P0T9K9 A0A7P0Z4B2 ENST00000576541.2 ENST00000680191.1 ENST00000680105.1 ENST00000680593.1 ENST00000570907.6 A0A7P0Z476 I3L4M2 ENST00000331483.9 ENST00000679455.1 ENST00000679439.1 ENST00000576052.2 Q8NI86 A0A7P0T8X1 ENST00000439918.7 I3L514 ENST00000679688.1 A0A7P0TAX9 ENST00000680416.1 A0A7P0Z4F8 H7BZ94 ENST00000576390.6 I3L3P5 ENST00000679889.1 ENST00000573778.7 A0A7P0T8C0 ENST00000680909.1 ENST00000681693.1 A0A7P0T8J3 ENST00000681420.1 A0A7P0T940 ENST00000576380.6 A0A7P0Z4S2 ENST00000681030.1 A0A7P0T9S9 ENST00000680846.1 ENST00000681566.1 ENST00000680400.1 ENST00000681760.1 ENST00000681515.1 ENST00000681161.1 A0A7P0TA97 A0A7P0TBP8 ENST00000680847.1 I3L0S0 ENST00000680884.1 ENST00000415593.6 I3L1Y5 A0A7P0T9D6 A0A7P0TA71 ENST00000574914.2 ENST00000681933.1 H0Y3Z3 A0A7P0Z4J0 ENST00000681031.1 ENST00000681020.1 ENST00000575069.6 |